首页> 外文期刊>Osteoarthritis and cartilage >Evaluation of the therapeutic effect of treatment with intra-articular hyaluronic acid in knees for Kashin-Beck disease: A meta-analysis
【24h】

Evaluation of the therapeutic effect of treatment with intra-articular hyaluronic acid in knees for Kashin-Beck disease: A meta-analysis

机译:kashin-beck疾病膝关节内静脉曲张透明质酸治疗治疗疗效的评价:META分析

获取原文
获取原文并翻译 | 示例
           

摘要

Objective: To assess the efficacy and safety of intra-articular hyaluronic acid (IAHA) injection in knee joints of patients with Kashin-Beck disease (KBD). Methods: We searched nine electronic databases as well as unpublished data from inception until November 30th 2013 using a combination of search terms for KBD and hyaluronic acid (HA). For dichotomous data, odds ratios (OR) and 95% confidence intervals (CI) were estimated. For continuous data, standard mean difference (SMD) was used for outcomes pooled on the difference scale using a "random-effects" or "fixed-effects" model. We also compared the mean and standard deviation of cytokine levels in post-treatment. Results: The seven eligible trials included 954 IAHA and 495 control patients. The methodological quality of included trials was low. The overall effectiveness of the IAHA group and control group were 93.7% and 62.9%, respectively. IAHA group resulted in very large treatment effects compared to pre-treatment values in 12 months, with SMD values ranging from 1.19-2.64 (all P<0.05). Compared to controls, SMDs in IAHA group ranged from 0.19-0.64 at 1 week to 1 month (all P>0.05) and 0.68-1.47 at 2 months to 12 months (all P<0.05). There was significant improved of HA, cluster of differentiation44 (CD44), keratan sulfate (KS), interleukin-1β (IL-1β), tumor necrosis factor-α (TNF-α) and nitric oxide (NO) contents in serum compared with that in the post-treatment and healthy control in non-KBD area (all P<0.05). Conclusion: IAHA for the treatment of KBD was safe and efficacious at 12 months with low and transient adverse reactions. However, more high-quality randomized controlled trials (RCTs) are needed to confirm its therapeutic effect.
机译:目的:评估关节内透明质酸(IAHA)注射患者kashin-beck疾病(KBD)膝关节内注射的疗效和安全性。方法:我们使用KBD和透明质酸(HA)的组合,搜索了九个电子数据库以及未发表的数据,从2003年11月30日开始到2013年11月30日。对于二分数据,估计了大量比率(或)和95%置信区间(CI)。对于连续数据,使用“随机效应”或“固定效应”模型,使用标准平均差(SMD)用于汇总差分级别的结果。我们还将细胞因子水平的平均值和标准偏差进行了处理后治疗方法。结果:七项符合条件的试验包括954个IAHA和495名控制患者。包括试验的方法论质量很低。 IAHA组和对照组的总体效果分别为93.7%和62.9%。与12个月内的预处理值相比,IAHA组导致非常大的治疗效果,SMD值范围为1.19-2.64(所有P <0.05)。与对照相比,IAHA集团的SMD在1周至1个月(全部P> 0.05)和0.68-1.47,在2个月至12个月(所有P <0.05)。 HA,分化44(CD44),角蛋白硫酸盐(Ks),白细胞介素-1β(IL-1β),血清中的肿瘤坏死因子-α(TNF-α)和一氧化氮(NO)含量的显着改善在非KBD区域的后治疗和健康控制中(所有P <0.05)。结论:Iaha在12个月内待治疗KBD,患有低和短暂的不良反应。然而,需要更高质量的随机对照试验(RCT)来确认其治疗效果。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号